Brief: VYNE Therapeutics Announces Dosing of First Subject in Phase 2b Vitiligo Trial of Novel BET Inhibitor VYN201

YARROW BIOSCIENCE

05/06/2024 13:05

June 5 (Reuters) - Vyne Therapeutics Inc  VYNE.O :
    * VYNE THERAPEUTICS ANNOUNCES DOSING OF FIRST SUBJECT IN
PHASE 2B
VITILIGO TRIAL OF NOVEL BET INHIBITOR VYN201

Source text for Eikon:  ID:nGNX5W7rgL 
Further company coverage:  VYNE.O 

 ((Reuters.Briefs@thomsonreuters.com;))